Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCW9302 in Alopecia Areata
NCT07049328Phase 1Recruiting
- Sponsor
- HCW Biologics
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HCW9302 in alopecia areata, sponsored by HCW Biologics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 9 weeks and Recommended Phase 2 Dose at 9 weeks. Started Aug 2025; status: recruiting.
02
Drugs
HCW9302
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT07049328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049328.